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ABSTRACT
Purpose: To evaluate and to compare macro and microscopically the intense injuries of the gastric mucosa of rats  which
were caused by NSAIDS celecoxib and indomethacin and the gastric cytoprotection with omeprazole and misoprostol.
Methods: The sample is formed by one hundred and fifty Wistar rats with average weight 200 g, distributed in four groups,
such as: Group A, subdivided in groups A1 and A2 – pre-treatment with omeprazole (20 mg/rat) during seven days and on
the 8th day – use of NSAIDS, concerning A1 (20 rats) were given celecoxib (1mg/rat) and A2 (20 rats) were given indomethacin.
The Group B, subdivided in group B1 and B2 – pre-treatment with misoprostol (20mg/rat) during seven days and on the 8th
day use of NSAIDS, concerning B1 (20 rats) were given celecoxib   (1 mg/ rat) and B2 (20 rats) were given indomethacin
(12.5 mg/rat). The Group C: were not given cytoprotection during seven days, from the 7th to the 8th day - fast of food and
water ad libitum, on the 8th day of NSAIDS use, concerning C1 (20 rats) were given celecoxib, C2 (20 rats) were given
indomethacin (12.5 mg/ rat), C3 (20 rats) were given celecoxib (200mg/rato), and Group D – control group, concerning 10
rats were observed during seven days ingesting food and water ad libitum. On the 9th day, the stomachs were taken out
and were macro and microscopically evaluated for the identification of the gastric injuries. Results: On the macroscopic
studies, the groups A2, B2 and C2 presented a remarkable high number of injuries for cm2 /animal, respectively  18.55
injuries for cm2 /animal, 16.25 injuries for cm2 /animal and 13.55 injuries for cm2/animal. On the microscopic studies, the
percentage of the injured mucosa, presented expressive difference among the groups A1, B1, C1 when compared to the
groups A2, B2, C2 (p<0.0001). The average of the length/injury and the average of the depth of the injuries did not present
expressive statistics differences among the groups A2, B2 and C2. The average of the edema presented expressive
statistics difference among the groups A2 and D; B2 and C2 and between C2 and D (p < 0.05). Conclusions: The indomethacin
on the applied concentration causes a great number of macroscopic and microscopic injuries to gastric mucosa of rats
when compared to celecoxib which does not cause lesions. Omeprazole and misoprostol on the applied concentrations do
not present macroscopic and microscopic effectiveness on the gastric cytoprotection when applying indomethacin.
Considering the microscopic analysis of the average of the edema, the group of animals, which was given misoprostol as
cytoprotection, presented a lower average compared to the group which was given omeprazole.
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RESUMO
Objetivo: Avaliar e comparar macro e microscopicamente as lesões agudas da mucosa gástrica de ratos provocadas pelos
AINEs celecoxib e indometacina e a citoproteção gástrica com omeprazol e misoprostol. Métodos: A amostragem consistiu
150 ratos machos da raça Wistar, com peso médio de 200g, divididos em quatro grupos, a saber: grupo A, subdividido em
grupos A1 e A2 – pré-tratamento com omeprazol (20 mg/rato) durante sete dias, e no oitavo dia receberam o AINEs, sendo
A1 (20 ratos) receberam celecoxib (1mg/rato) e A2 (20 ratos) receberam indometacina (12,5mg/rato). O grupo B, subdividido
em grupo B1 e B2 – pré-tratamento com misoprostol (20ìg/rato) durante sete dias e no oitavo dia receberam AINEs, sendo
B1 (20 ratos) receberam celecoxib (1mg/rato) e B2 (20 ratos) receberam indometacina (12,5mg/rato). O grupo C não recebeu
citoproteção durante sete dias e no oitavo dia recebeu AINEs, sendo C1 (20 ratos) receberam celecoxib (1mg/rato) , C2
(20ratos) receberam indometacina (12,5mg/rato), C3 (20 ratos) receberam celecoxib  e grupo D – grupo controle, no qual dez
ratos foram observados recebendo ração e água ad libitum. A seguir, no 9º dia (de todos os grupos), os estômagos eram
removidos e avaliados macro e microscopicamente para a identificação das lesões gástricas. Resultados: Na análise
macroscópica, os grupos A2, B2 e C2 apresentaram número de lesões por cm2/animal significativamente elevados, sendo
respectivamente 18,55 lesões por cm2/animal, 16,25 lesões por cm2/animal e 13,55 lesões por cm2/animal. Na análise
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microscópica, a porcentagem da mucosa com lesão mostrou diferença significativa entre os grupos A1, B1, C1 quando
comparados com os grupos A2, B2 e C2 (p<0,0001). Os resultados da média da extensão/lesão e da média da profundidade
das lesões não mostraram diferenças estatísticas significativas entre os grupos A2, B2 e C2. A média do edema mostrou
diferença estatística significativa entre os grupos A2 e D; B2 e C2 e entre C2 e D (p<0,05). Conclusões: A indometacina na
concentração empregada provoca número significativo de lesões macro e microscópicas na mucosa gástrica de ratos
quando comparadas ao celecoxib, que não provocou  lesões. O omeprazol e o misoprostol nas concentrações empregadas
não mostraram efetividade macro e microscópica na citoproteção gástrica à administração da indometacina. Considerando-
se a análise microscópica da média do edema, o grupo de animais que recebeu misoprostol como citoprotetor apresentou
menor média em comparação ao grupo que recebeu o omeprazol.
Descritores: Antiinflamatórios não Esteróides. Mucosa Gástrica. Estômago. Farmacologia.
Introduction
The specialized literature points out that 300 million of
people all over the world use non steroidal anti-
inflammatories drugs (NSAIDs) and 1.2% of the population
in the USA take these agents everyday.  Also, 100 million of
NSAIDs prescriptions yearly, are considered 1,2. Actually,
8% of the old population has, at least, one chronic disease
and most of them have two, and an important information is
that there will be approximately 750 million of people aged
more than 65 years old in the world until 2050. The use of
medicaments increases according to the age, mainly due to
the amount of diseases which are higher 3.
The use of several medicaments causes many
symptoms and gastrointestinal diseases, and it is important
to stress that the digestive diseases are significant causes
of old people’s morbidity and mortality 3. The long period
of NSAIDs use causes erosions in the gastroduodenal
mucosa to approximately 35% - 60% of the patients, peptic
or duodenal ulcers to 10% - 25% and serious complications,
such as hemorrhage or gastrointestinal perforation 4.
Considering only the patients who have rheumatoidal
arthritis, 20.000 hospitalizations and 2,600 deaths a year are
registred, due to the toxicity related to NSAIDs. Exceeding
these data, considering all the population who uses NSAIDs
in the United States, more than 100,000 hospitalizations and
10,000 to 20,000 deaths a year are due to the gastrointestinal
complications related to NSAIDs, having a cost exceeding
4 billion a year 5,6.  Not only patients aged more than 65
years old but also young people can have gastric injuries
caused by NSAIDs 7,8. These studies show the importance
of the upper digestive endoscopy, which detect even
asymptomatical injuries 9.
The upper  digestive endoscopy studies on rheumatic
patients who had a long periods of treatments with NSAIDs,
confirmed a high incidence of gastric and duodenal lesions.
The ocurrence for peptic ulcers was 17% and erosions 40%;
for duodenal ulcers 4% and erosion 13% 10. Otherwise,  the
physiopathology of the peptic diseases can be considered
as an unstability among the injurious factors (acid, pepsin,
infection by Helicobacter pylori) and the protective factors
(bicarbonate secretion, mucous and prostaglandins). The
current treatments are directed to the reduction of the
injurious factors and to strength the mucosa protections of
the stomach and duodenum through the cytoprotector
agents 9.
The antacids were the unique neutralizers of the gastric
acid used to relieve the symptoms of the ulcers during
several years. Although the gastric acidity had been
responsible as the main etiologic factor of the peptic ulcer,
the researches pointed toward the ways where the gastric
mucous usually protect itself from injurious agents
suggesting additional terapeutic focus. The new drugs
which reduce the acid gastric secretion  (H2  blockers  and
the inhibitors of the bomb proton) promote the ulcer
cicatrization and they are the most used ones. The
cytoprotector agents (sucralfate, colloidal bismuth and the
misoprostol) and the antacids also have confirmed
efficiency in the literature 11.
The main therapeutical effects of NSAIDs are its ability
of inhibits the prostaglandin synthesis,  whose
generalization is performed in a progressive way throughout
a abnormal complex of enzymes. The first enzyme which
takes part of this procedure is the synthesis of the
prostaglandin endoperoxide, also known as ciclooxygenase.
There are two isoforms of this enzyme, ciclooxygenases 1
and 2 (denominated COX-1, COX-2). The first one is a
determinative isoform, found in the blood vessels, stomach
and livers, which acts as gastric cytoprotector while COX-
2 is induced in the inflammatory context by the citokines
and intermediaries of the inflammation 12.
The NSAIDs, besides having several therapeutical
activities in common, however present many side effects,
such as: ulceration and gastrointestinal intolerance;
changes in the platelet aggregation (inhibition of the
tromboxano synthesis); decreasing of the uterine motility
(extension of the pregnancy; decreasing of the renal
functions interfered by the prostaglandins and
hypersensitivity reactions 13.
Considering all the side effects mentioned above, the
most common one, regarding the facts, is the tendency to
produce gastric or intestinal ulceration which, in some cases
associated with a secondary bleeding and anaemia  . Other
authors show that patients who take NSAIDs for long
periods of time, have three times more chance to develop
collateral gastrointestinal complications, compared to the
patients who do not take these drugs 14.
Recently a new NSAIDs named “coxibs”.arise, having
complications rate lower than the traditional drug, The
“coxibs” represent an important pharmacological advance
in the anti-inflammatory treatment, reducing the
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gastrointestinal injuries, once they are specific inhibitor of
the COX-2 15. Regarding the gastric cytoprotector, there are
several therapeutic strategies, according to the following
distribution: antacid agents, cytoprotector agents,
antagonists of H2 receptor, muscarínic antagonist, agonists
of prostaglandin and inhibitors of H+, K+ - ATPase 11. The
statistics of serious injuries caused to people who use
NSAIDs all over the world and the importance of the gastric
cytoprotection, besides the recent advances with the
introduction of drugs with seletive inhibitor of the COX-2,
therapeutical advancements were afforded, once this enzyme
probably is involved in the production of prostaglandins
10,14. The objective of this research is to study  the  injuries
caused by indomethacin  and celecoxib and compares the
cytoprotector action of the omeprazole and misoprostol.
Methods
The research had previous approval by The Ethic
Committee on the Animal Trial in the Biology Institute. One
hundred and fifty male Wistar rats, three months old and
200g average weight, being considered healthy and free
from specific diseases (SPF – Specific Pathogen Free), were
employed. The animals were arranged in groups of 10, they
had been kept in environmental temperature, with daylight
cycles, under a continuous air flow; they were given food
and water ad libitum, always remaining in the same cage
until the end of the study. The cages were always handled
by the same laboratory expert, who was especially trainned
for this position. He wore suitable footwears, aprons and
gloves and cleaned the cages three times a week.
Drugs and dilution
All the drugs were administrated intragastrically:
• Indometacin   : 12,5mg/ rat, dilluted in fltrate water (01
cachet – 25mg in 2ml) – (groups A2; B2 and C2) –
(Indocid® – Prodome Laboratory)
• Celecoxib ® : one 200mg tablet, dilluted in 200ml of water
(1mg/ rat) – (Groups A1 and C1); one 200mg tablet
dilluted in water (200mg/ rat) – (Group C3) – (Celebra ®
-  Pharmacia Laboratory– Brasil Ltda).
• Omeprazole  : 20mg/ rat – 1 tablet (20mg) diluted in 1ml
of water – (Group A1) – Losec ®  -  Astrozenica
Laboratory)
• Misoprostol  : one tablet (200µg)/ 10 rats: dillution of 1
tablet in 20ml (2µ/rat) – (Group B1) – (Cytotec® -
Pharmacia Laboratory – Brasil Ltda)
Animal groups and experimental design
The animals were put in cages, there were five rats in
each one, which were distributed in groups of 20 ones.
Group A: Pre-treatment with omeprozole
Group A1: celecoxib – 20 rats
Group A2: indomethacin – 20 rats
Forty rats were pre treated daily (during 7 days) with
omeprazole. From the 7th to the 8th day, they fasted for 24
hours, 20 of them were given celecoxib and 20 were given
indomethacin. After taking NSAIDs, they fasted for 6 hours.
So, the animals were sacrificed on the 9th day, due to
anaesthetic overload of sodic tiopental and the stomach
were removed for  examination of the gastric injuries.
Group B: Pre-treatment with misoprostol
Group B1: celecoxib – 20 rats
Group B2: indomethacin – 20 rats
Forty rats were pre-treated daily (during 7 days) with
misoprostol. From the 7th to the 8th day, they fasted for 24
hours, 20 of them were given celecoxib and 20 were given
indomethacin. After taking NSAIDs, they fasted for 6 hours.
Again,  the animals were sacrificed on the 9th day due to
anaesthetic overload of sodic tiopental  and the stomach
were removed for examination of the gastric injuries.
Group C: no cytoprotection
Group C1: celecoxib (1mg/ rat) – 20 rats
Group C2: indomethacin – 20 rats
Group C3: celecoxib (200mg/ rat) – 20 rats
Sixty rats were not protected with cytoprotector drug,
they fasted during 24 hours before taking NSAIDs, 40 of
them were given celecoxib and 20 were given indomethacin,
fasting for more six hours after taking NSAIDs and were
sacrificed on the following day.
Group D: Control
Ten animals were kept and observed in the Laboratory
during 9 days and just fed with usual food and water ad
libitum. Between the 8th and the 9th days, the animals fasted
for 24 hours. After this period, they were sacrificed and had
their stomachs removed, according to the technique
described previously. The animals were observed daily in
order to verify the possible behavior and/or physiological
changes. All the animals were given rodent common food,
ad libitum, and it was changed  once a week.
Euthanasia of the animals
The stomach of the animals were removed through a
laparotomy,  exposition of the abdominal cavity after they had
been anaesthetized with sodic tiopental. The internal part of
the removed stomachs were given 2ml of bungged formalin
7,2% and 5 minutes afterward, they were opened through the
greater curvature,  from the pylorus to the cardia. After the
surgical parts were removed, the animals were submitted to
euthanasia through overload of sodic tiopental.
Macroscopic analysis
The stomach, when opened, was put on a flat glass
plate in order the injuries could be counted, according to
Takagi et al. 16 standardization. In order to count the injuries,
a 10x10cm squared glass plate was made, according to the
following Figure 1.
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Afterwards, the injuries were counted, putting the
squared glass plate on the flat glass plate, according to the
following Figure 2. The fragments were divided
longitudinally, and at least, less than half of the stomach of
each animal was included at random on the histopathologic
screens for arrangement. Then, the screens, containing the
fragments, were first plunged into  7,2% formaldehyde
during 24 hours and then into alcohol 70% for 72 hours.
Afterwards, the histological cuts were carried through.
end, the histologic investigations was carried out through
a light microscope with objectives and binocular viewer
which generated a final magnification  200 and 400 times. In
the microscopic analysis the following were evaluated:
a) Percentage of the mucosa of each animal which had
injury, was computed according to the formula below
and the results were shown as percentage of the
injured mucosa 16.
Percentage of the injured mucosa =  
 =      horizontal extension of the injuries
               total extension of the fragments
b) The extension, the depth and the edema of each injury
16, considering:
b.1) Horizontal extension in mm of each injury and the
results shown as extension/injury average;
b.2) Depth of the injuries, for each one, the
comparative depth of each injury was computed,
according to the following formula.
comparative depth =
The results are shown as average of the injury depth,
in percentage
b.3) Edema of the injuries; for each injury the edema
index was computed according to the following
formula :
oedema index =            submucosa thickness
       thickness of the muscular layer
The results are shown as quotient of the edema average.
Results
Macroscopic analysis
The averages of the injuries per cm2 /animal are shown
in the Figure 3, as the following groups of animals:
Group A: Group of animal which were given as pre-treatment
(cytoprotection): omeprazole and afterwards they were
given NSAIDs celecoxib or indomethacin (Figure 3).
Group A1: Group of animals which were given
celecoxib, after a pre-treatment with omeprozole. 4
injuries per cm2  were found, therefore an average of 0,2
injuries per cm2 /animal.
Group A2: Group of animals which were given
indomethacin, after a pre-treatment with omeprozole.
371 injuries per cm2 were found relating to an average
of 18,55 injuries per cm2 /animal . So the amount of
FIGURE 1 - 10x10cm flat glass plate, squared (1cmx1cm)
FIGURE 2 - Opened stomach, overlaid squared flat glass
plate, exposing the mucous, showing the
counting methodology of the injuries per cm2
Microscopic analysis
The pieces were cut using razor of Leika 858 section
and arranged in histologic screens, performing longitudinal
cuts. The fragments were dehydrated by crescent alcohol,
made diaphanous with xylol, included into paraffin and
undergone microthome adjusted to 5 µm thickness  and
coloured by Hematoxylin and Eosin (HE) technique. At the
Depth of the erosive or ulcerative injury
Depth of the mucosa
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injuries per cm2/animal in the group A2 was
significantly higher than the group A1.
Group B: Group of animal which were given as pre-treatment
(cytoprotection): misoprostol and afterwards they were
given the NSAIDs celecoxib or  indomethacin (Figure 3).
Group B1: Group of animals which were given celecoxib
after a pre-treatment with misoprostol, 9 injuries per
cm2 were found, totalizing, therefore, the average of
0,45 injuries per cm2/animal.
Group B2: Group of animals which were given
indomethacin after a pre-treatment with misoprostol.
325 injuries/ cm2 were found, therefore the average of
16,25 injuries per cm2/animal. This way, the amount of
injuries per cm2/animal in the group B2 was significantly
higher than the group B1.  Figure 4 shows these results.
Group C: No cytoprotection (Figure 3).
Group C1: Group of animals which were given celecoxib
(1mg/rat). Macroscopic injuries were not found in the
animals’ mucosa.
Group C2: Group of animals which were given
indomethacin. 271 injuries per cm2 were found, which
corresponds to the average of 13,55 injuries per cm2/
animal. The data above show that the amount of
injuries per cm2/animal in the group C2 was significantly
higher than the group C1.
Group C3: Group of animals which were given celecoxib
(200mg/rat). Macroscopic injuries were not found in
the animal’s mucosa.
Group D: Control. Animals which were given just water and
usual food during the trial and none injuries were found.
b) Extension, depth and edema of each injury.
b.1) Average of the extension/injury showed in the Figure 5
FIGURE 3 - Average of the injuries per cm2 /animal in the
group of animals which were given celecoxib
(A1) and indomethacin (A2) respectively, after
a pretreatment with omeprazole
Microscopic analysis
a) Percentage of the injured mucosa showed in the Figure 4.
FIGURE 4 - Diagram “Box and Whiskers” of the microscopy
study of the injured mucosa percentage,
showing the percents 5, 25, 50, 75 and 95 of
each studied group. The statistic analysis
through Kruskall Wallis trial showed
expressive difference among the groups A1,
B1, C1 and A2, B2, C2 (p< 0.0001)
FIGURE 5 - Diagram “Box and whiskers” of the microscopic
study of the extension average/injury in mm,
showing the percentis 5, 25, 50, 75 and 95 of each
studied group. The statistic analysis through
Kruskall Wallis trial did not show difference
among the groups A2, B2 and C2 (p=0.62)
b.2) Average of the injury depth showed in the Figure 6.
b.3) Edema average showed in the Figure 7.
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The statistic analysis through Kruskall Wallis trial
showed difference between the groups A2 and D; B2 and
C2 and between C2 and D2 (p<0,05)
c) In the correlations through Spearman trial among all the
analyzed items, when the injured mucosa percentage and
the injury depth average were compared, an expressive
statistic difference came out in the groups A2 and C2
(p<0,05). However, a relevant statistic difference in the
group B2 (p>0,05) was not verified. So, in the group B2
(misoprostol + indomethacin) the lowest oedema average
among the other groups A2 (omeprazole + indomethacin)
and C2 (indomethacin) was verified
Correlations of the Hystopatologic Findings and the
respective statistic analysis
Kruskall Wallis trial will be used in order to perform the
statistic analysis of these groups, a non parametric trial, in
which the average and the standard declination are not
considered but it is used for the asymmetry in the
distribution of the data.  Besides, at the end, all the possible
correlation were performed among the 5 analyzed items,
using the Spearmen Correlation statistic trial for the groups
A2, B2 and C2 in order to compare the results among the
groups 17 .
Discussion
The experimental research performed with laboratory
animals has been the base of the knowledge and the
biological science, physiology, pharmacology evolution and
the physiopatology  understanding which manage the
therapeutic trials. The results of these trials must be
evaluated carefully and possibly will be applied in human
beings. The dog, the rat and the mouse are the laboratory
animals which are used in most of the trial researches, mainly
in Brazil; making use of dogs is necessary larger spaces, in
order they can be observed for a long period of time.
Otherwise, the rat and the mouse, as they are small, they
can be used in great number, taking little space, then having
less costs of maintainance 18.
Other important aspect to be stressed is that the
interpretations of the trial results which were performed
using drugs in laboratory animals depend on the period  of
time of the treatment and the amount and concentrations
which were used. Therefore these values must be evaluated
carefully several times for each animal or group of animals
during the study, considering its race, weight and biological
age and these controls usually are not simple and easy.
Thus, comparing the results among several similar
researches to get the conclusions, these factors must be
considered. The conclusions of the researches which have
been gotten in laboratory animals can not be interchanged
totally to the human being, but indeed they provide
important contributions of what possibly would occur to
the human being, that the longevity of the population, in
general, has risen during last decades as well as the quality
of life 9.
The peptic ulcers can be provided in laboratory animals
by several methods, but the importance of these models for
comparative studies in humans is controversy. These ulcer
models, established over the past 35 years, highly resemble
human ulcers in terms of both pathological features and
healing process 16,19,20. Despite, we preferred in this research,
to named simply gastric injuries or gastric effects  all the
macro and microscopic lesions found in the gastric mucosa.
The male and young adult Wistar rats were chosen and
about  the dosage of the used drugs, they were gotten from
the products which are commonly found at most of the
drugstores, and the same concentrations used for a 60 Kg
adult, accurately arranged for the weight of the animals,
showing exactly the same effects and consequences which
could occur in the humans. The NSAIDs have a primary
action in the ciclooxygenases (COX-1 and COX-2)
decreasing the prostaglandin synthesis. The inhibition of
COX-2 seems to interfere, at least in some parts, the
antipyretic, analgesic and anti-inflammatory actions of the
FIGURE 6 - Diagram “Box and Whiskers” of the microscopic
study of injury depth average showing the
percentis 5, 25, 50, 75 and 95 of each studied
group. The statistic analysis through Kruskall
Wallis trial did not show difference among the
groups A2, B2 and C2 (p=0.70)
FIGURE 7 - Diagram “Box and Whiskers” of the
microscopic study of the edema average
quotient, showing the percentis 5, 25, 50,
75 and 90 of each studied group
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NSAIDs, but the simultaneous decreasing of the COX-1
causes undesirable side effects, mainly the peptic ulcers
and gastric erosions, resultant from the reduced synthesis
of prostaglandins. There are many side effects referred to
NSAIDs, but the individual response of the patients is still,
probably, the most important 13,14,21.
The celecoxib  is included in a new class of NSAIDs
with complication rates significantly lower than the
conventionals,  which also provides analgesic and
antipyretic effects 22. It was the first compound to be
approved by “Food and Drug Administration”(FDA) to be
used in the USA, in 1998 15,23. Regarding its pharmacologic
and pharmacocinetic properties, it is believable that its action
is due to the prostaglandin synthesis inhibition, mainly
through the selective COX-2 inhibitor. Therefore, its
therapeutical concentrations do not hinder the COX-1 which
produce the prostaglandins involved in the maintenance of
the gastrointestinal mucosa erosion, in the aggregation of
the platelets and in the kidney action 24,25.
All the “coxibs”, due to the saving of COX-1, were
introduced as a new nonsteroidal anti-inflammatory class
having equivalent efficacy.  Recently other medicaments of
the same group have risen in the market, the etoricoxib,  the
valdecoxib. At last, the parecoxib the first specific inhibitor
of the COX-2 for parental use has also been introduced for
clinical use 22,25.
It is important to emphasize that the therapeutical
conventional uses of the indomethacin develop undesirable
symptoms in 35% to 50% of the patients and about 20% of
them need to stop the treatment. Most of the side effects
depend on the prescribed dosage. The complaints and the
gastrointestinal complications are the most relevant and
consist in anorexia, nausea and abdominal pain. Simple
ulcers or multiple ulcerations in all the upper gastrointestinal
treatment have been described, sometimes with perforations
and hemorrhage. The hidden loss of blood in the excrement
can cause anemia, even without ulceration. It must not be
used by pregnant woman, fosters, professionals which work
on machines or patients who have psychiatric disorder,
epilepsy or parkinsonism and is also formally counter
indicated to people who have kidney illness or stomach or
intestine ulcer injuries 9,14,26,27.
Laudanno et al. 28 studying the effects of ulcerogenic
doses of celecoxib and indomethacin on Wistar rats gastric
mucosa showed that celecoxib does not induce
gastrointestinal lesions in healthy mucosa. However,
celecoxib given after indomethacin aggravated antrum
gastric ulcers, intestinal massive necrosis and death were
observed in all the rats. They concluded that celecoxib
ampliflies the gastrointestinal lesions induced by
indomethacin.
Coppelli et al. 29 recently studied the gastric effects of
celecoxib  in rats by measuring gastric potential difference
and mucosal lesions. The results indicated that celecoxib
did not alter gastric mucosal barrier nor induced mucosal
lesions in healthy rat gastric mucosa.
The pharmacological and pharmacokinetic effects of
the omeprazole, used to treat gastritis, peptic ulcers and
esophagitis,  result in the reduction of the gastric secretion
through a high selective action, providing specific
decreasing of the  enzyme H+, K+ - ATPase (proton pump)
in the parietal cells, having no action in the acetylcholine
and histamine receptors. Therefore, there are just small
changes in the gastric juice, pepsin secretion and intrinsic
factor and do not affect the gastric motility 11,27.
The capacity of several prostagladin analogous to
control and prevent the gastric ulceration, known as
cytoprotection, is a very important therapeutical property.
The PGE1 (misoprostol) and PGE2 analogous have been
studied clinically, once they are predominantly synthesized
by the gastric mucosa, decreasing the acid secretion and
bicarbonate. The prostaglandins protects the gastric
mucosa of animals against several ulceration attack. The
ulceration properties of nonsteroidal anti-inflammatories
which hinder the prostaglandin syntheses interfere in the
regular gastric action, therefore several prostaglandin
analogous which had a slow metabolism were developed
and tested in humans 4.11,25.
Misoprostol is a powerful abortive and must not be
used by pregnant women or women who can be pregnant,
this is a very important factor which can also limit its use 30.
The specific literature studies in humans emphasizes that
peptic ulcers were healed in eight weeks with the inhibitor
of proton pump – omeprazol (83%), when compared to the
prostaglandin analogous – misoprostol (74%). Moreover,
the side effects, such as diarrhea and abdominal pain were
more commonly in patients who were treated with
misoprostol.  Clinical studies which aim to evaluate the cost
benefit in the prevention of  peptic ulcer caused by
conventional NSAIDs caused by NSAIDs, showed
comparisons between omeprazol and misoprostol.
Omeprazol is more efficient and has better cost benefit in
the treatment of gastric and duodenal ulcers. Therefore,
omeprazol is the  choice for ulcer treatment along with the
NSAIDs, taking as basis its efficiency, tolerance and safety
– 20mg ideal dosage once a day 31,32.
Topaloglu et al. 33 produced acute gastric mucosal
lesions in Wistar rats using Brodie’s protocol (stress method)
and then administrated omeprazole or famotidine. They
concluded that omeprazole prevents acute gastric mucosal
erosions more effectively than famotidine. Okabe et al. 20 in
recent overview about acid ulcer models reported many
researchs of anti-secretory drugs, mucosal defense agents,
gene therapy with epidermal growth factor, vascular
endothelial growth factor, nitric oxid and others involved in
experimental ulcer healing. Similar experimental research
which had been performed here was not found in the
examined literature. The results showed expressive
differences of values, regarding the amount of lesions
caused by the indomethacin in the gastric mucosa of rats,
when compared to the amount of lesions caused by
celecoxib. The celecoxib not caused macro and microscopic
gastric lesions, even when administrated in high doses (200
mg/rat). About the average of the edema, the results show
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expressive statistics difference among the groups,  and the
group of animals, which was given misoprostol as
cytoprotection, presented a lower average compared to the
group which was given omeprazole (p < 0.05). Besides,
omeprazole and misoprostol have not seemed to be
completely effective in the prevention of the injuries caused
by indomethacin.
Consequently, these data, once more, confirm the
importance of the finding macro and microscopic
comparisons. These new NSAIDs class, having less
injurious effect in the gastric mucosa have a higher cost
when compared to conventional drugs,  but certainly they
are a new therapeutical tendency regarding the efficacy of
based in better quality of life and reduction of the patients’
side effect rate.  Meanwhile these advantages mean more
than such costs,  which is primordial in order celecoxib can
start being prescribed as a choice drug for certain diseases
instead of prescription of conventional NSAIDs which have
lower costs related to preventive cytoprotection. Certainly,
news experimental and clinical researchs , including NSAIDs
and their pharmacological actions and their side effects in
the gastroduodenal mucosa, are necessary in the future,
trying to make clear controversial issues which still are.
Conclusions
The indomethacin on the applied concentration causes
a great number of macroscopic and microscopic injuries to
gastric mucosa of rats when compared to celecoxib which
does not cause lesions. Omeprazole and misoprostol on
the applied concentrations do not present macroscopic and
microscopic effectiveness on the gastric cytoprotection
when applying indomethacin. Considering the microscopic
analysis of the average of the edema, the group of animals,
which was given misoprostol as cytoprotection, presented
a lower average compared to the group which was given
omeprazole.
References
1. Bateman DN.  NSAID´S: Time to re-evaluate gut toxicity.
Lancet. 1994; 343: 1051-2.
2. Paulus  HE.  FDS Artthritis Advisory Committee meeting:
postmarketing surveillance of   nonsteroidal
antiinflammatory drugs. Arthritis Rheumatol. 1985;28:
1168-9.
3. Schneider EL. Aging in the third millennium.
Science.1999; 283:796-7.
4. Schmassmann  A.  Mechanisms of ulcer healing and
effects of nonsteroidal anti-inflammatory drugs. Am J
Med. 1998;104:43S-51S.
5. Griffin  Mr . Epidemiology of nonsteroidal anti-
inflammatory drug- associated gastrointestinal injury.
Am J Med.1998;104(suppl.1):23S-29S.
6. Fries JF.  NSAID gastropathy: the second most deadly
rheumatic disease? Epidemiology and risk appraisal. J
Rheumatol.1991; 18(suppl. 28): 6-10.
7. Vreeburg  EN,  Snel  P,  De Brujine JW.  Acute upper
gastrointestinal bleeding in the   Amsterdam area :
Incidence, diagnosis, and clinical outcome. Am J
Gastroenterol. 1997;  92:236-43.
8. Segal, WN, Cello  JP. Hemorrhage in the upper
gastrointestinal tract in the older  patient.  Am J
Gastroenterol.1997; 92: 42-6.
9. Mccarthy  DM . Nonsteroidal antiinflammatory drug
induced ulcers : management by   traditional therapies.
Gastroenterology.1989; 96:662-74.
10. Barrison I . Prophylaxis against non-steroidal induced
upper gastrointestinal side  effects.   Ann Rheumatol
Dis. 1991; 50: 207-9.
11. Brunton  LL. Fármacos para controle da acidez gástrica
e tratamento de úlceras pépticas.  In: Goodman LS, Gilman
A, Hardman JG. As bases farmacológicas da terapêutica.
9.ed. Rio de Janeiro: Mc Graw Hill; 1996. p. 663-74.
12. Smith  WL.   Prostanoid   biosynthesis  and    mechanism
of   action. Am J  Physiol.1992;  268:181-91.
13. Borda  IT,  Koff  RS.  Nsaids. A profile of adverse effects.
Philadelphia: Hanley and Belfus Inc; 1992.
14. Gabriel  SE,  Jaakkirnainen  L,  Bombardier C.  Risk for
serious gastrointestinal complications related to use of
nonsteroidal antiinflammatory drugs:  a meta-analysis.
Ann Intern Med.1991; 115 (suppl.1): 787-96.
15. Whelton  A.  Renal  aspects  of  treatment  with
conventional  nonsteroidal anti – inflammatory  drugs
versus  cyclooxygenase – 2  specific inhibitors. Am J
Med.  2001; 110:33S-42S.
16. Takagi K,  Okabe S,  Saziki, R.  A  new  method  for  the
production  of chronic gastric ulcer in rats and the effect
of several drugs on its healing. Jpn Pharmacol.1969;
19:418-26.
17. Conover  WJ.  Practical  nonparametric  statistics. New
York: John Wiley & Sons; 1971.
18. Bralow  SP.   Experimental gastric carcinogenesis.
Digestion. 1972; 5: 290-310.
19. Silen  W.  Experimental   models   of   gastric   ulceration
and   injury.  Am Phys Soc. 1998;24:395G-402G.
20. Okabe S,  Amagase  K.  An overview of acetic acid ulcer
models—the history and state of the art of peptic ulcer
research. Biol Pharmacol Bull.  2005; (8):1321-41.
21. Brooks  P. Use and benefits of nonsteroidal  anti-
inflammatory drugs. Am J Med.1998; 104(suppl.1): 43S-51S.
22. Cheer  SM,  Goa  Kl.  Parecoxib (parecoxib sodium). Drugs.
2001; 61: 1133-41.
23. Chan  CC,  Boyce  S,  Brideau  C.  Rofecoxib (VioX.MK-
0966,4- (4 methylsulfonylphenyl)-3-phenyl-2-(5H)-
furanone): a potent and orally active cyclooxygenase-2
inhibitor-pharmacological and biochemical profiles. J
Pharmacol      Exp      Ther. 1999; 290(suppl.1): 551-60.
24. Silverstein  FE,  Faich  G,  Goldstein  JL . Gastrointestinal
toxicity with celecoxib vs nonsteroidal anti-inflammatory
drugs for osteoarthritis and rheumathoid  arthritis. J Am
Med Assoc. 2000;284:1247-55.
25. Cannon   GW,  Breedveld  Fc.  Efficacy of
cyclooxygenase-2 specific inhibitors. Am   J Med.
2001;110(suppl.1): 6S-12S.
26. Jonsson  B,  Wahlqvist  P.  Management of nonsteroidal
anti-inflammatory drug-associated lesions: a cost–
effectiveness  perspective. Am J Med.1998;104(suppl.1):
81S-8S.
27. Mctavish  D,  Buckley MM, Heel RC.  Omeprazole: an
updated review of its pharmacology and therapeutic use
Cavallini ME et al
176 - Acta Cirúrgica Brasileira - Vol 21 (3) 2006
in acid-related disorders. Drugs.1991; 42:138-70.
28. Laudanno OM,  Esnarriaga J M,  Cesolari  JA, Maglione
CB,  Aramberry  LJ, Sambrano  JS,  Piombo  G,  Rista  L.
Celecoxib vs indomethacin and acute gastric lesions in
rats.  Medicina. 2000;60(2):221-4.
29. Coppelli G,  Guaita  E, Spaggiari  S, Coruzzi  G. Gastric
effects of the selective cyclooxygenase-2 inhibitor,
celecoxib, in the rat. Dig Liver Dis. 2004;36(4):265-70.
30. Collins  PW.  Misoprostol: discovery, development, and
clinical applications. Med Res Rev.1990; 10:149-72.
31. Hawkey  CJ . Progress in prophylaxis against nonsteroidal
anti- inflammatory drug-associated ulcers and erosions.
Am J Med.1998; 3A(104): 67S-74S.
32. Yeomans  Nd. New data on healing of nonsteroidal anti-
inflammatory drug-associated  ulcers and erosions. Am
J Med.1998; 104:56S-61S.
33. Topaloglu  U,  Muftuoglu T,  Akturk  Z,  Ekinci  H,  Peker
O,  Unalmiser  S. Omeprazole is more effective than
famotidine for preventing acute gastritis in rats.  Surg
Today. 2004;34(8):690-4.
Conflict of interest: none
Financial source: none
Received: December 18, 2005
Review: January 22, 2006
Accepted: February 13, 2006
Correspondence:
Miriam Elias Cavallini
Rua Tiradentes, 490/62
13400-760  Piracicaba – SP  Brazil
Phones: (55 19)3433-2040 / 9788-4343
mielias@merconet.com.br
How to cite this article:
Cavallini ME, Andreollo NA, Metze K, Araújo MR. Omeprazole and misoprostol for preventing gastric mucosa effects
caused by indomethacin and celecoxib in rats. Acta Cir Bras. [serial on the Internet] 2006 May-June 21(3). Available from
URL: http://www.scielo.br/acb.
*Color figures available from www.scielo.br/acb
Da esquerda para direita: Renato Santos de Oliveira Filho,
Saul Goldenberg, Luiz Gonzaga Porto Pinheiro
REGIONAL DO CEARÁ DA SOBRADPEC
Presidente Luiz Gonzaga Porto Pinheiro
Instalou o LABORATÓRIO DE CIRURGIA EXPERIMENTAL
PROF. DR. SAUL GOLDENBERG
Cirurgia Radioguiada
-Linfonodo Sentinela-
Iniciativa do Grupo de Educação e
Estudos Oncológicos (GEEON) e da
Faculdade de Medicina da Universidade
Federal do Ceará
A solenidade de inauguração do
Laboratório, com posicionamento de
placa comemorativa, foi realizada em 17
de março de 2006, em Fortaleza-Ceará.
